1. Home
  2. TRVI vs SDGR Comparison

TRVI vs SDGR Comparison

Compare TRVI & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$10.15

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$16.47

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVI
SDGR
Founded
2011
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
TRVI
SDGR
Price
$10.15
$16.47
Analyst Decision
Strong Buy
Buy
Analyst Count
12
10
Target Price
$20.38
$24.90
AVG Volume (30 Days)
1.3M
903.8K
Earning Date
03-17-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$256,951,000.00
Revenue This Year
N/A
$23.69
Revenue Next Year
N/A
$20.32
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.90
52 Week Low
$3.73
$15.99
52 Week High
$14.39
$28.47

Technical Indicators

Market Signals
Indicator
TRVI
SDGR
Relative Strength Index (RSI) 34.14 38.08
Support Level $10.17 $16.07
Resistance Level $11.15 $17.87
Average True Range (ATR) 0.73 0.77
MACD -0.13 -0.20
Stochastic Oscillator 3.52 9.83

Price Performance

Historical Comparison
TRVI
SDGR

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Share on Social Networks: